EnglishУкраїнська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Yakimenko O.O., Appelhans O.L., Maznichenko Ye.O.

    CORRECTION OF THE LIVER MORPHO-FUNCTIONAL STATE IN EXPERIMENTAL NON-ALCOHOLIC STEATHEPATITIS AND HYPERCHOLESTERINEMIA


    About the author: Yakimenko O.O., Appelhans O.L., Maznichenko Ye.O.
    Heading EXPERIMENTAL MEDICINE
    Type of article Scentific article
    Annotation The purpose of the work was to study the dynamics of morphological and functional changes in the liver during complex lipid-lowering therapy in NASH with hypertension in rats. The study was carried out on the Wistar line rats. The animals were divided into groups: intact; control for NASH and HCh; I - rats with NASH and HCh treated with rosuvastatin "Rosuvastatin IS" 0.3 mg / kg per day, 45 days; II - rats with NASH and GB treated with rosuvastatin 0.3 mg / kg per day and omega-3 PUFAs (Epadol Neo), 45 days; III - rats with NASH and HCh receiving rosuvastatin 0.3 mg / kg per day and hepatoprotector "Gepadif", 45 days. Modeling of the pathology occurred 90 days through the use of an atherogenic diet. Animals were removed from the experiment on the forty-fifth day of treatment. The formation of NASH with HCh lasted 90 days. On the forty-fifth day of monotherapy with rosuvastatin in animals of group I, the level of atherogenic lipoproteins decreased, but the activity of liver enzymes and the histological picture did not change significantly. In the second group, a more expressive hypolipidemic effect was found, the concentration of TG was significantly lower compared to group I and the control group, the expressiveness of steatosis was lower. In group III, significant decrease in the levels of TCh, LDL, an increase in HDL, a decrease in the activity of hepatic transaminases, reproduction of the liver structure, and a decrease in steatosis were revealed. The use of rosuvastatin and complex hepatoprotectors led to an expressive lipid-lowering effect and reproduction of the morphological and functional status of the liver in animals with simulated NASH and HCh.
    Tags hypercholesterolemia; non-alcoholic steatohepatitis; statin; omega-3 polyunsaturated fatty acids, hepatoprotector
    Bibliography
    • Bazylevych AYa. Nealkoholnyi steatohepatyt yak novyi faktor rozvytku ishemichnoyi khvoroby sertsya. Scient. J «ScienseRise». 2015; 10/3(15): 171-5. [in Ukrainian]
    • Zaichko NV, Nekrut DO. Vplyv omeha-3 polinenasychenykh zhyrnykh kyslot ta symvastatynu na markery tsytolizu, dyslipidemiyi ta oksydatyvnoho stresu u shchuriv z nealkoholnoyu zhyrovoyu khvoroboyu pechinky, asotsiyovanoyu z hiperhomotsysteyinemiyeyu. Visnyk problem bioloh..i med.2017; 2(136): 123-9. [in Ukrainian]
    • Mayevskaya MV, Morozova MA. Vozmozhnosti korrektsii dislipidemii u patsiyentov s nealkogolnoy zhirovoy boleznyu pecheni. Gepatol.2016; 26(4): 55-61. [in Russian]
    • Maksymchuk OV. Vplyv ō-3 polinenasychenykh zhyrnykh kyslot na ekspresiyu fermentiv pro- ta antyoksydantnoyi systemy v pechintsi shchuriv. Fiziol.zhurn. 2017;60(3): 32-7. [in Ukrainian]
    • Myrzabayeva NA. Gepadif v gepatologicheskoy praktike: dostizheniya, perspektivy (obzor literatury). Gepatologiya.2015; 10: 76-80. [in Russian]
    • Statsenko ME, Turkina SV, Kosivtsova MA, Tyshchenko IA. Nealkogolnaya zhirovaya bolezn pecheni, kak multisistemnoye zabolevaniye. Vestnik VolgGMU.2016; 2(58): 8-14. [in Russian]
    • Kholodkova OL, Maznichenko YEO. Patent na korysnu model "Sposib modelyuvannya nealkoholnoho steatohepatytu v shchuriv" № 132515 Nomer zayavky u2018. 10224, Data publikatsiyi ta nomer byuletenya 25.02.2019 Byul. №4. [in Ukrainian]
    • Gidding SS, Champagne MA, Ferranti SD, Defesche J, Matthew K, Ito MK  et al The agenda for Familial Hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. Dec.2015; 132(22): 2167 - 92. doi:10.1161/CIR.000000000000029.
    • Hirsova P, Ibrahim SH, Gores GJ, Malhi M. Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. J. Lipid Res. 2016; 57(10): 1758-70. doi: 10.1194/jlr.R066357.
    • Kanda T, Matsuoka S, Yamazaki M, Shibata T, Nirei K, Takahashi H et al. Apoptosis and non-alcoholic fatty liver diseases.World J. Gastroenterol. 2018; 24(25): 2661-72. doi: 10.3748/wig.v24.i25.2661.
    • Kim EJ, Kim BH, Seo HS, Lee YJ, Kim HH, Son HH at al. Cholesterol-induced non-alcoholic fatty liver disease and atherosclerosis aggravated by systemic inflammation. PloS One. Jun. 2014; 9(6): e97841. doi: 10.1371/journal.pone.0097841. eCollection 2014.
    • Sulivan EM, Pennington ER, Green WD, Beck MA, Brown DA, Shaikh SR. Mechanisms by which dietary fatty acids regulate mitochondrial structure-function in health and disease. Adv.Nutr. May 2018; 9(3): 247-62p. doi: 10.1093/advances/nmy007
    • Tajiri K, Futsukaichi Y, Kobayashi S, Yasumura S, Takahara T, Minemura M et al. L-carnitine for the treatment of over hepatic encephalopathy in patients with advanced liver cirrhosis.J.Nutr. Sci. Vitaminol. 2018; 64(5): 321-28. doi: 10.3177/jnsv.64.321
    • Wang HH, Garruti G, Liu M, Porthincasa D, Wang DQ. Cholesterol and lipoprotein metabolism and atherosclerosis: recent advances in reverse cholesterol transport. Ann Hepatol. Nov. 2017: 16(1, 3-105.): 27-.42. doi:10.5604/01.3001.0010.5495.
    • WGO Global Guidelines NAFLD/NASH, 2012, 32 p.
    Publication of the article «World of Medicine and Biology» №3(69), 2019 year, 239-244 pages, index UDK 616.36-002-003.826-06 : 616.153.922]-091/-092-08
    DOI 10.26724/2079-8334-2019-3-69-239-244